Analysts Set Smith & Nephew plc (LON:SN) Price Target at GBX 1,310

Smith & Nephew plc (LON:SN) has been given a consensus rating of “Hold” by the nine ratings firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 1,310.

A number of equities analysts recently issued reports on the stock. Berenberg Bank dropped their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a report on Friday, August 14th. Citigroup cut shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. UBS Group reiterated a “neutral” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday, May 5th. Shore Capital Group reiterated a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a research note on Tuesday, July 21st. Finally, Royal Bank Of Canada cut their price objective on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research report on Thursday, August 6th.

Smith & Nephew Stock Up 0.3%

Smith & Nephew stock opened at GBX 1,071 on Friday. The company has a market cap of £11.74 billion, a P/E ratio of 38.56, a P/E/G ratio of 0.46 and a beta of 0.69. The company has a current ratio of 2.14, a quick ratio of 0.84 and a debt-to-equity ratio of 73.07. The company’s 50-day moving average price is GBX 1,125.57 and its 200-day moving average price is GBX 1,178.89.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.